News – Page 1147 – Endpoints News

Eau de poop: Bill Gates tests a new way to sweeten the world’s worst odors

9 years ago

Booming rare disease player Shire adding a trendy new R&D hub in Kendall Square for 1,000-plus

9 years ago

It’s a tie: Sanofi and Novo come in neck-and-neck at the FDA with two new diabetes combo OKs

9 years ago

After a painful stumble, AstraZeneca gets top checkpoint cancer program back on track

9 years ago

Aduro gets back on track with CRS-207 after FDA lifts partial clinical hold

9 years ago

Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug

9 years ago

Chiesi picks a pipeline fight with Novartis, going head-to-head on a big new target for asthma

9 years ago

Acorda writes off another R&D program as Ampyra flops in stroke study

9 years ago

Novartis swoops in to bag Selexys and its sickle cell drug in $665M deal

9 years ago

Goodbye, San Francisco. Stanford spinout heads to Houston after bagging a $20M CPRIT grant

9 years ago

Dinner and a biotech chat: Billionaire Patrick Soon-Shiong talks 'innovation' with President-elect Trump

9 years ago

MD Anderson to biotech billionaire Soon-Shiong: Get your own slogan. ‘Moon Shots’ belongs to us

9 years ago

Donald Trump is starting to win over biopharma

9 years ago

Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash

9 years ago

Florida's decade-old incentive program to lure research institutions is going belly up

9 years ago

Gilead punts hep B drug as GlobeImmune joins the (dead quiet) ranks of zombie biotechs

9 years ago

Spectrum floats new PhIII idea after FDA slaps down failed bladder cancer drug

9 years ago

Gilead needs to stop waiting and start buying; Let's embrace China as a new biopharma power

9 years ago

J&J takes one of its top blockbuster prospects to the FDA, in search of a big approval

9 years ago

Fledgling biotech Syntimmune looks to take flight in the clinic with a new CEO and a slightly less virtual business ...

9 years ago

No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent

9 years ago

Another South San Francisco biotech campus takes shape; WSJ: Feds plan charges in Valeant kickback scheme

9 years ago

Grunenthal snags a PhIII-ready orphan drug in Thar Pharma buyout

9 years ago

Amgen, Novartis are racing to regulators with positive PhIII migraine data, but rivals are in hot pursuit

9 years ago

First page Previous page 1144 1145 114611471148 1149 1150 Next page Last page